VentriPoint Diagnostics Ltd. is a medical device company, which engages in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is headquartered in Toronto, Ontario. The company went IPO on 2005-11-09. The company is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. The company develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. The company provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. The company has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
Follow-Up Questions
What is the price performance of VPTDF stock?
The current price of VPTDF is $0.08, it has decreased 0% in the last trading day.
What are the primary business themes or industries for VentriPoint Diagnostics Ltd?
VentriPoint Diagnostics Ltd belongs to Health Care industry and the sector is Health Care
What is VentriPoint Diagnostics Ltd market cap?
VentriPoint Diagnostics Ltd's current market cap is $13.4M
